ABO Incompatible Hematopoietic Stem Cell Transplants – A Review and Impact to Transfusion

Please note: AABB reserves the right to make updates to this program.

Live Program Date: Wednesday, February 26, 2020 - On-Demand Available

Master Program Number: 20EL-509 (see program format numbers below under Registration)

Educational Track: Scientific
Topic: Transfusion Medicine
Intended Audience: CEOs, COOs, Director, Donor Recruitment Staff, Hospitals, Hospital Blood Banks, Laboratory Staff, Managers/Supervisors, Medical Directors, Nurses, Physicians, Research/Fellow, Scientists, Student (MD, MT, SBB), Technologists
Teaching Level: Intermediate

Director/Moderator: Suchi Pandey, MD, Clinical Associate Professor, Stanford University School of Medicine Chief Medical Officer, Stanford Blood Center, Palo Alto, CA
Speakers: Claudia Cohn, MD, PhD, Associate Professor of Laboratory Medicine and Pathology, Director, Blood Bank Laboratory, Associate Director, Clinical Laboratories, Chief Medical Officer, AABB, University of Minnesota, Minneapolis, MN; Jennifer C. Andrews, MD, Associate Professor of Pathology, Microbiology and Immunology, Associate Professor of Pediatrics, Medical Director, Blood Bank, Vanderbilt University Medical Center, Nashville, TN

Learning Objectives

After participating in this educational activity, participants should be able to:

  • Provide an update on ABO incompatible HSCT including a review of potential complications.
  • Discuss transfusion support issues following ABO-incompatible HSCT.
  • Review data/information relating to ABO-incompatible HSCT from different facilities including protocols for transfusion support, monitoring for hemolysis, and switching blood type.

Program Description

ABO-incompatible hematopoietic stem cell transplantations (HCST) are frequently performed. Patients require significant transfusion support primarily with RBCs and Platelets until engraftment occurs. This program will provide an update on ABO-incompatible HSCT and review potential complications such as immediate and delayed hemolysis. Speakers will share information and data on ABO-incompatible HSCTs from their institutions and review protocols for transfusion support and blood typing of patients following an ABO-incompatible HSCT.


   Program #
Single Viewer: On-Demand Register20EL-509-4035
Group Viewing: On-Demand Register20EL-509-8035

Continuing Education Credit

AABB designates both the live and on-demand version of this eCast each eligible for 1 continuing education credits/contact hours for Physicians, General Participation, California Nurse, California Lab Personnel and Florida Lab Personnel. The number and type of credits awarded for this program (both live and on-demand) was determined by the program duration. For more information on each credit type please visit our Continuing Education Credits webpage.

Disclosures for the planners of this event can be found here. Disclosures for the program faculty are provided at the beginning of the program.

Speaker Biography

Dr. Claudia Cohn earned her PhD in Immunology and Infectious Diseases from the Johns Hopkins University (currently the Bloomberg School of Public Health) and subsequently earned her MD at Louisiana State University. After finishing her Transfusion Medicine fellowship at University of California, San Francisco, Dr. Cohn joined the faculty at the University of Minnesota, in Minneapolis, where she is Medical Director of the Blood Bank, Associate Medical Director of the HLA lab and Associate Head of Labs. Dr. Cohn’s major interests include platelet support for stem cell transplant patients, hemovigilance and appropriate use of blood components. She is Editor-in-Chief of the upcoming AABB Technical Manual (20th edition), and Associate Editor of the International Society of Blood Transfusion (ISBT) Science Series, which is dedicated to publishing manuscripts on transfusion/blood banking in resource-limited countries. Dr. Cohn has served in the AABB Clinical Transfusion Medicine committee, Transfusion Standards committee and the Transfusion Transmitted Disease committee.

Dr. Jennifer Andrews completed her residency in Pediatrics at the University of North Carolina-Chapel Hill in 2007, her fellowship in Pediatric Hematology/Oncology at Emory University in 2011, and her fellowship in Transfusion Medicine/Blood Banking at Stanford in 2012. She was a Clinical Assistant and Associate Professor of Pathology and Pediatrics at Stanford from 2012 until she joined the faculty at Vanderbilt in the summer of 2018 and subsequently became the Medical Director of the Blood Bank. Dr. Andrews practices benign Hematology at Monroe Carell Jr. Children's Hospital and Transfusion Medicine. Dr. Andrews serves as the Principle Investigator for several clinical trials and her research interests include pediatric transfusion medicine, alloimmunization in patients with sickle cell anemia and leveraging technology to improve blood utilization.